Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)

Bibliographic Details
Main Authors:	Simon L. Parsons, Tom McCulloch, Mike Sokal, Sarah Khan, Gurprit S. S. Atwal, Abraham A. Ayantunde, Elizabeth M. Pinder
Format:	Article
Language:	English
Published:	Hindawi Limited 2007-01-01
Series:	Sarcoma
Online Access:	http://dx.doi.org/10.1155/2007/82012

Similar Items

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours
by: Lucy C. Scott, et al.
Published: (2005-01-01)

Effects of STI571 (gleevec) on pancreatic cancer cell growth
by: Büchler Markus W, et al.
Published: (2003-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec&reg;, Gleevec&trade;)
by: Martin Henkes, et al.
Published: (2008-03-01)

Biological activity of the 2-phenylaminopyrimidine class receptor tyrosine kinase inhibitor imatinib mesylate (STI571) in malignant glioma
by: Ren, Huan
Published: (2005)

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro
by: Turner Steven, et al.
Published: (2003-01-01)

Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.
by: Dariush Mokhtari, et al.
Published: (2011-01-01)

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
by: Abbas Agaimy, et al.
Published: (2013-03-01)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01)

Étude de l'altération de la réponse aux radiations ionisantes par deux inhibiteurs de tyrosine kinase : le STI571 (Glivec®) et le BIBW 2992
by: Huguet, Florence
Published: (2010)

Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
by: Bérengère Gobin, et al.
Published: (2014-01-01)

Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR
by: Seyed Ataollah Sadat Shandiz, et al.
Published: (2016-02-01)

Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil
by: Marcos Lima
Published: (2005-09-01)

Imatinib mesylate-induced palmoplantar keratoderma
by: Niharika Jha, et al.
Published: (2021-01-01)

Periorbital edema secondary to imatinib mesylate
by: Collin M McClelland, et al.
Published: (2010-05-01)

Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles
by: You-Zhe Lin, et al.
Published: (2021-06-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)

The teratogenic effects of imatinib mesylate on rat fetuses
by: M.M. El Gendy, et al.
Published: (2015-01-01)

Bi-specific Aptamers mediating Tumour Cell Lysis
by: Boltz, Achim
Published: (2011)

Acute renal failure in patients with tumour lysis sindrome
by: Poskurica Mileta, et al.
Published: (2016-01-01)

Spontaneous Tumour Lysis Syndrome in a Multiple Myeloma
by: Can Huzmeli, et al.
Published: (2016-01-01)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019-07-01)

The role of c-kit and imatinib mesylate in uveal melanoma
by: Pereira Patricia, et al.
Published: (2005-10-01)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008-03-01)

Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab
by: Mohamad Jaffer Abdalkhalig Mustafa, et al.
Published: (2017-01-01)

Study on the neutrophil MMP-8 and MMP-9 expression in STI571-treated CML patients
by: 廖書嫻
Published: (2002)

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
by: Lori Rink, et al.
Published: (2013-01-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Anti-Diabetic and Beta-Cell Protective Actions of Imatinib Mesylate
by: Hägerkvist, Robert
Published: (2006)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Imatinib in PDGFR positive malignant solitary fibrous tumour of the pleura
by: Sarah Bigeni, et al.
Published: (2016-03-01)

Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours
by: Andersson, Anna
Published: (2008)

Influence of hypoxia on tumour cell susceptibility to cytotoxic T lymphocyte mediated lysis
by: Noman, Muhammad Zaeem
Published: (2012)

Influence of hypoxia on tumour cell susceptibility to cytotoxic T lymphocyte mediated lysis
by: Noman, Muhammad zaeem
Published: (2012)

Acute Respiratory Distress Syndrome Associated with Tumour Lysis Syndrome in Leukemia
by: Chaim M Bell, et al.
Published: (1997-01-01)

Cannot write session to /tmp/vufind_sessions/sess_dgt0ofa8rpn6d1gudg0980dq5a